Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery

Abstract

Abstract Background: The introduction of endovascular surgery has led to frequent stent use, although in-stent restenosis (ISR) remains a challenging issue. Drug-coated balloon (DCB) and conventional balloon angioplasty (BA) are common endovascular procedures for addressing ISR in the femoropopliteal artery. However, there is controversy regarding which procedure provides the greatest benefit to patients. Methods: The PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched for prospective controlled trials that compared DCB and BA for patients with ISR in the femoropopliteal artery. The study has been approved by Ethics Committee of Wuhan Central Hospital. Results: The meta-analysis included 6 prospective trials with 541 patients. We found that DCB use was associated with significant reductions in binary restenosis at 6\u200amonths (relative risk [RR]: 0.45, 95% confidence interval [CI]: 0.33–0.63; P\u200a<\u200a.00001), binary restenosis at 1\u200ayear (RR: 0.44, 95% CI: 0.34–0.57; P\u200a<\u200a.00001), target lesion revascularization (TLR) at 6\u200amonths (RR: 0.36, 95% CI: 0.20–0.65; P\u200a=\u200a.0006), and TLR at 1\u200ayear (RR: 0.38, 95% CI: 0.27–0.54; P\u200a<\u200a.00001). The DCB group also had significantly better clinical improvement (RR: 1.39, 95% CI: 1.13–1.71; P\u200a=\u200a.002), although we did not detect inter-group differences in terms of death, target vessel thrombosis, or ipsilateral amputation. The brand of DCB may a cause of heterogeneity. Conclusion: Relative to BA, DCB use increases the durability of treatment for ISR in the femoropopliteal artery, based on significant reductions in binary restenosis and TLR at 6–12\u200amonths after the procedure. Furthermore, DCB use was associated with better clinical improvement. However, additional randomized controlled trials are needed to validate these findings.